

## Technology Advisory Committee A Interests Register

### Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer [ID3755]

Publication Date: 31 March 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TA Committee A Member	Non-financial professional & personal interest	Member of the Evidence Review Group for this topic	NA	11/12/2020	NA	It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Duncan Wheatley	Clinical Expert	Direct financial interest	Previously been on advisory boards for Novartis.	NA	09/09/2020	NA	It was agreed that this declaration would not prevent Dr Wheatley from providing expert advice to the committee.
Holly Heath	Patient Expert	Indirect interest	Holly's employer, Breast Cancer Now, has received funding from Novartis.	NA	15/10/2020	NA	It was agreed that this declaration would not prevent Holly from providing expert advice to the committee.